share_log

Intelligent Bio Solutions | 8-K: Current report

Intelligent Bio Solutions | 8-K: Current report

Intelligent Bio Solutions | 8-K:重大事件
美股SEC公告 ·  04/12 08:32

Moomoo AI 已提取核心訊息

Intelligent Bio Solutions Inc., a medical technology company listed on Nasdaq under the symbol INBS, announced on April 11, 2024, the expansion of its intellectual property portfolio with the grant of a new European patent for its subsidiary, Intelligent Fingerprinting Limited. The patent, which has unitary effect, covers the DSR-Plus Cartridge Reader, a device that facilitates non-invasive, rapid drug screening through fingerprint sweat analysis. This technology is particularly useful in workplace and safety-critical environments. The European patent enables the company to enforce its rights in 17 European countries, marking a significant step in Intelligent Bio Solutions' strategy to expand its global presence and offer its advanced solutions to a wider market. The company's CEO, Harry Simeonidis, expressed enthusiasm for the expansion into the European market and the potential to enhance workplace safety and health. The DSR-Plus Cartridge Reader is noted for its efficiency, providing results in less than ten minutes, and is part of the company's broader aim to revolutionize portable testing across various applications.
Intelligent Bio Solutions Inc., a medical technology company listed on Nasdaq under the symbol INBS, announced on April 11, 2024, the expansion of its intellectual property portfolio with the grant of a new European patent for its subsidiary, Intelligent Fingerprinting Limited. The patent, which has unitary effect, covers the DSR-Plus Cartridge Reader, a device that facilitates non-invasive, rapid drug screening through fingerprint sweat analysis. This technology is particularly useful in workplace and safety-critical environments. The European patent enables the company to enforce its rights in 17 European countries, marking a significant step in Intelligent Bio Solutions' strategy to expand its global presence and offer its advanced solutions to a wider market. The company's CEO, Harry Simeonidis, expressed enthusiasm for the expansion into the European market and the potential to enhance workplace safety and health. The DSR-Plus Cartridge Reader is noted for its efficiency, providing results in less than ten minutes, and is part of the company's broader aim to revolutionize portable testing across various applications.
Intelligent Bio Solutions Inc. 是一家在納斯達克上市的醫療技術公司,股票代碼爲INBS,該公司於2024年4月11日宣佈擴大其知識產權組合,爲其子公司智能指紋有限公司授予一項新的歐洲專利。該專利具有統一效力,涵蓋了DSR-Plus墨盒讀取器,該設備通過指紋汗液分析促進非侵入性的快速藥物篩查。這項技術在工作場所和安全關鍵環境中特別有用。這項歐洲專利使該公司能夠在17個歐洲國家行使其權利,這標誌着Intelligent Bio Solutions擴大其全球影響力併爲更廣泛的市場提供先進解決方案的戰略邁出了重要一步。該公司首席執行官哈里·西蒙尼迪斯對向歐洲市場的擴張以及提高工作場所安全與健康的潛力表示了熱情。DSR-Plus 卡式讀卡器以其效率著稱,可在不到十分鐘的時間內提供結果,這是該公司徹底改變各種應用的便攜式測試的更廣泛目標的一部分。
Intelligent Bio Solutions Inc. 是一家在納斯達克上市的醫療技術公司,股票代碼爲INBS,該公司於2024年4月11日宣佈擴大其知識產權組合,爲其子公司智能指紋有限公司授予一項新的歐洲專利。該專利具有統一效力,涵蓋了DSR-Plus墨盒讀取器,該設備通過指紋汗液分析促進非侵入性的快速藥物篩查。這項技術在工作場所和安全關鍵環境中特別有用。這項歐洲專利使該公司能夠在17個歐洲國家行使其權利,這標誌着Intelligent Bio Solutions擴大其全球影響力併爲更廣泛的市場提供先進解決方案的戰略邁出了重要一步。該公司首席執行官哈里·西蒙尼迪斯對向歐洲市場的擴張以及提高工作場所安全與健康的潛力表示了熱情。DSR-Plus 卡式讀卡器以其效率著稱,可在不到十分鐘的時間內提供結果,這是該公司徹底改變各種應用的便攜式測試的更廣泛目標的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息